Advertising and marketing of medical devices in the EU: seminar/webinar 8 June in Amsterdam

Advertising and marketing of medical devices is a subject I see many clients struggle with. Unlike with medicinal products EU law in the field of advertising and marketing is almost not harmonised. Consequently multi-jurisdictional advertising and marketing campaigns are difficult for companies, as they need to take a lot of different national laws into account, as I and colleagues have described in this article. To provide some clarity for those interested I thought it would be a good idea to organise a seminar / webinar on the subject, please click here for your invitation.

Given the very different enforcement climates in different EU national jurisdictions I have invited Alexander Denoon from the UK and Mathias Klümper from Germany, both partners in life sciences niche firms, to join as speakers. We will bring you up to date on the latest EU law developments in the field, as well as discuss how you can avoid the regular pitfalls with international advertising and marketing for medical devices in the EU. There will be ample opportunity for questions of course.

If you cannot make it in person, you can always consider attending the webinar. Any interested is welcome to attend, whether in person or in the webinar, so feel free to forward the invitation to whomever you think might be interested.

Navigate through our knowledgebase

Related articles


Regulatory pathways for clean meat in the EU and the US – differences & analogies

Now that the US regulatory framework is shaping up, the analogies and differences with the European regulatory framework for market access for clean meat becomes more and more clear. This blogpost reports these analogies and differences, based on the agreement that the FDA and USDA recently concluded on their cooperation in the field of clean […]


Cannabis derived food products – what’s the current state of play?

Recently, CBD food products were qualified as Novel Foods requiring a market authorization. The lively trade in these products therefore currently seems to be at risk. However, not all cannabis derived products…

Read more


What to expect for 2019 with MDR and IVDR implementation?

Remember the CAMD Roadmap (dating back to end 2017) that promised us a roll-out of MDR and IVDR items that were sometimes even marked ‘high priority’ and how that lifted our spirits (at the time)? Remember how this was supplemented with the Rolling Plan, which promised the roll-out of all roll-outs for 2019? I have […]